Telescope Upgrade Reveals Sun's ‘Coronal Rain' in Unprecedented Detail
A powerful new optics system has captured the clearest view yet of the Sun's corona, revealing stunning plasma structures.
The Sun's outer atmosphere—the corona—is the piping hot outer limit of our star, and is usually hidden from view except during rare total eclipses. Now, scientists have gotten their clearest look ever at this mysterious region, thanks to a new adaptive optics system that scrubs away atmospheric blur, revealing fine views of the wispy plasma on the star's surface.
Researchers from the National Solar Observatory and New Jersey Institute of Technology unveiled the system today, along with dazzling new images and videos of the Sun's corona. The findings, published in Nature Astronomy, show fine-scale structures in solar prominences, short-lived plasma jets called spicules, and even coronal rain: cooling plasma that falls back to the solar surface along the star's magnetic field lines.
The team's imaging breakthrough hinges on a technology called coronal adaptive optics. Installed on the 5.25-foot (1.6-meter) Goode Solar Telescope in California, the new system—nicknamed 'Cona'—adjusts a mirror 2,200 times per second to correct for distortions caused by the churn of Earth's atmosphere. The remarkable technology counterbalances any would-be wobble in the telescope, thereby producing particularly sharp images of the corona.
'This technological advancement is a game-changer,' said Dirk Schmidt, an adaptive optics scientist at NSO and the study's lead author, in an observatory release. 'There is a lot to discover when you boost your resolution by a factor of 10.'
Until now, solar telescopes have used adaptive optics mainly to study the Sun's surface, the release stated. Observing the fainter corona has remained a challenge, with coronal features blurred to scales of 621 miles (1,000 kilometers)—a limit that's existed for 80 years. But Cona now resolves features down to just 39 miles (63 km), the theoretical limit of the Goode telescope.
Among the new footage captured by the team are shots of a twisting solar prominence reshaping in real time, spicules flickering on the surface, and fine, hair-like strands of coronal rain narrower than 12.5 miles (20 km). When you consider how far the Sun is from Earth, how faint the corona is relative to the rest of the star, and how much of Earth's turbulent atmosphere the team had to cut through and correct for, the sharpness of the images is a triumph.
'This transformative technology, which is likely to be adopted at observatories world-wide, is poised to reshape ground-based solar astronomy,' said study co-author Philip Goode, a physicist at NJIT-CSTR, in the same release. 'With coronal adaptive optics now in operation, this marks the beginning of a new era in solar physics, promising many more discoveries in the years and decades to come.'
The observations offer crucial data for unraveling enduring solar mysteries—like why the corona is millions of degrees hotter than the solar surface.
The team plans to bring the coronal adaptive optics technology to the 13-foot (4-meter) Daniel K. Inouye Solar Telescope in Hawaiʻi—potentially revealing even smaller details of the Sun's atmosphere.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
New Data Show Delve Bio's Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing
Data Presented at the 2025 American Society for Microbiology Microbe Conference BOSTON, June 22, 2025--(BUSINESS WIRE)--Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at the American Society for Microbiology (ASM) Microbe conference in Los Angeles showing the impact of metagenomic sequencing for transforming infectious disease diagnostics by offering advances compared to traditional microbiological testing. Among the data presented at the meeting is a comparison of Delve's metagenomic cerebrospinal fluid (CSF) test, Delve Detect CSF, compared to a traditional PCR-based meningitis/encephalitis (ME) panel. The study reanalyzed samples from a diverse patient cohort previously tested using the ME panel. The data showed that mNGS can be used in conjunction with microbiological testing to increase diagnostic yield by identifying pathogens that are not detectable with traditional, pathogen-specific panel testing. The inclusion of mNGS tests like Delve Detect, which has a 48-hour turnaround time, can shorten time to diagnosis, enabling clinicians to initiate targeted therapies sooner. "This study showed substantial agreement between Delve Detect and a syndromic PCR panel. But importantly, Delve Detect also identified pathogens that were not included on the PCR panel and would have been missed as causes of a patient's infection if mNGS were not included in the diagnostic workup," said Benjamin Bradley, M.D., Ph.D., medical director of virology and molecular infectious diseases at ARUP Laboratories. "This study supports including mNGS in the diagnostic workup for patients with complex central nervous system infections." The study included 122 samples — 47 positive and 75 negative. Analysis showed that in comparison with the ME panel, Delve Detect CSF demonstrated approximately 10% higher positivity rate (48% vs. 38%), with an additive diagnostic yield of 24%. This added yield included detection of multiple co-infections, 16 unique organisms not included in the ME panel, and positive detections in 19 samples (25%) that were negative by the ME panel. Additionally, in samples that were negative by both tests, Delve Detect CSF showed high agreement (95%) with the ME panel, supporting the negative predictive value of mNGS. The company's full presence at ASM Microbe 2025 includes: Delve's chief medical officer Steve Miller, M.D., Ph.D. hosted A New Era: Metagenomic Sequencing for Comprehensive Pathogen Detection, exploring real world evidence, clinical cases and considerations for laboratory teams implementing mNGS. Presentation of a case report in a feature poster, Using Metagenomic Sequencing to Diagnose a Novel Moraxella CNS Shunt Infection in a Culture-Negative Case Presentation of data comparing the company's mNGS CSF test, Delve Detect, to a widely used, PCR meningitis/encephalitis panel as part of the session Assessing the Clinical Impact of Next-Generation Sequencing: Where Are We Now? "These presentations at ASM highlight the transformation underway in infectious disease diagnostics. Delve Bio's metagenomic sequencing technology enables clinicians to identify the cause of serious central nervous system infections when existing methods do not deliver a diagnosis and speed is critical," said Brad Murray, chief executive officer of Delve Bio. "We're working to make this technology more widely available to neurologists, infectious disease physicians and laboratory teams so they can get patients the answers they need." Conference attendees are also invited to visit Delve Bio at booth #1440 to learn more about the company's metagenomic platform, including Delve Detect and its proprietary bioinformatics platform Delve Decide. Delve Detect is Delve Bio's flagship metagenomic testing service, providing comprehensive pathogen detection with a 48-hour turnaround time after sample receipt and including access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts who review results in clinical context. About Delve Bio, Inc. Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit View source version on Contacts Company Contact Amy WongSenior Director of Marketing and Business Development, Delve BioEmail: media@ Media Contact Julie McKeough42 North for Delve BioEmail: julie@ Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Should You Forget Bitcoin and Buy Solana?
Solana has underperformed Bitcoin over the past year. It faces a lot of competitive threats. It has catalysts on the horizon -- but it could struggle to stand out. 10 stocks we like better than Solana › Bitcoin's (CRYPTO: BTC) price surged about 60% over the past 12 months and trades about 7% below its all-time high. That rally was driven by an inflow of cash into its spot price ETFs, which started trading last year; more corporate and institutional purchases, and the Trump administration's crypto-friendly stance and establishment of a Strategic Bitcoin Reserve. Bitcoin could also be gaining more traction as a hedge against inflation, geopolitical conflicts, and other macro headwinds, while expectations for lower interest rates are driving investors toward the crypto market again. Yet many of the smaller cryptocurrencies were left behind and underperformed Bitcoin. One of those tokens was Solana (CRYPTO: SOL), which only rose about 7% over the past 12 months and remains more than 50% below its all-time high. Let's see why Solana slipped -- and if it might be a better long-term investment than Bitcoin at these levels. Solana, like Ether (CRYPTO: ETH), is staked on its blockchain (locked up for interest-like rewards) instead of mined. That proof of stake (PoS) mechanism consumes a lot less power than the proof of work (PoW) mechanism used to mine Bitcoin. PoS blockchains also support smart contracts, which are used to develop decentralized apps (dApps), games, non-fungible tokens (NFTs), and other crypto assets. PoW blockchains are only used for mining tokens and don't support those developer-oriented features. Therefore, Solana and other PoS tokens are often valued by the speed of their transactions and the growth of their developer ecosystems instead of the scarcity of their tokens. Moreover, Solana is an inflationary token with no maximum supply. Nearly 528 million Solana tokens are currently in circulation, but it's reducing its annual inflation rate (currently at 4.5%) by 15% every "epoch year" (450 days to 630 days) until it reaches an annual inflation rate of 1.5%. Bitcoin is a deflationary cryptocurrency with a maximum supply of 21 million tokens, 19.9 million of which have already been mined. That scarcity makes Bitcoin more comparable to gold, silver, and other physical commodities. Many PoS tokens were built on Ethereum's blockchain, but Solana has its own native PoS blockchain. Solana also upgraded that PoS blockchain with its proprietary proof-of-history (PoH) mechanism, which enables it to process transactions at a faster rate than Ethereum. Solana has a theoretical maximum speed of 65,000 transactions per second (TPS), compared to a theoretical max speed for 30 TPS for Ethereum's main Level 1 transactions. But for real world transactions, which face network congestion and other limitations, Solana has a daily average speed of 600 to 1,500 TPS, while Ethereum has an average Level 1 speed of 15 TPS. However, other Level 2 solutions which are built on top of Ethereum and process the transactions off-chain can achieve much higher real-world speeds of 1,000 to 4,000 TPS. Rollups, which bundle together multiple transactions off-chain to be processed together, are the most common type of Level 2 solutions on Ethereum. So while Solana is the fastest PoS blockchain, it's still less popular than Ethereum because its ecosystem is smaller, it's not cross-compatible with other blockchains, and its main developer languages (Rust and C) have steeper learning curves than Ethereum's Solidity. Solana also had more network congestion and outage issues than Ethereum. Those challenges caused Solana to underperform Bitcoin over the past year. But looking ahead, a few catalysts could elevate its profile and drive its price higher. Visa, Shopify, and other companies have integrated Solana Pay into their platforms to process instant and near-free stablecoin transactions. Meanwhile, more developers are launching games on Solana which use in-game NFTs, tokens, and other crypto collectibles. Some developers are also launching new decentralized projects -- like wireless networks, GPU sharing, and decentralized real-world maps -- on Solana's blockchain. New network upgrades should reduce its congestion and improve its scalability. Last but not least, several crypto firms recently submitted their applications for Solana ETFs. It's unclear if the Securities and Exchange Commission (SEC) will actually approve those new funds, but they could help Solana attract a lot more attention from institutional investors. Solana's speed and growth potential make it a more promising investment than many of the other "meme coins." That said, I don't think it's a better crypto investment than Bitcoin for three simple reasons: It's inflationary, it faces lots of competition from Ethereum's L2 solutions, and it isn't cross-compatible with other blockchains like Ethereum. Before you buy stock in Solana, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Solana wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Leo Sun has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bitcoin, Ethereum, Shopify, Solana, and Visa. The Motley Fool has a disclosure policy. Should You Forget Bitcoin and Buy Solana? was originally published by The Motley Fool Sign in to access your portfolio
The Verge
an hour ago
- The Verge
OpenAI and Jony Ive's ‘io' brand has vanished, but their AI hardware deal remains
OpenAI has scrubbed mentions of io, the hardware startup co-founded by famous Apple designer Jony Ive, from its website and social media channels. The sudden change closely follows their recent announcement of OpenAI's nearly $6.5 billion acquisition and plans to create dedicated AI hardware. OpenAI tells The Verge the deal is still happening, but it scrubbed mentions due to a trademark lawsuit from Iyo, the hearing device startup spun out of Google's moonshot factory. The announcement blog post and a nine-minute video featuring Ive and OpenAI CEO Sam Altman are no longer available. The blog post from Ive and Altman announcing the deal said, 'The io team, focused on developing products that inspire, empower and enable, will now merge with OpenAI to work more intimately with the research, engineering and product teams in San Francisco.' OpenAI spokesperson Kayla Wood: This page is temporarily down due to a court order following a trademark complaint from iyO about our use of the name 'io.' We don't agree with the complaint and are reviewing our options.
